Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

Novavax hitched its wagon to the global coronavirus pandemic. Before most Americans truly grasped the scope of the danger, the small Maryland biotech startup had secured $1.6 billion in U.S. funding for its covid vaccine. Its moonshot goal: delivering 2 billion shots to the world by mid-2021. Although the U.S. commitment eventually expanded to $1.8 billion, […]